Fundz

Who to call at Alector, Inc., and when

Fundz watches for the moments Alector, Inc. starts buying, and tells you who to reach.

  • An alert the day Alector, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Alector, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Alector, Inc.. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KHIGH RiskNegative

Alector, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

alector.com
Filed: Oct 21, 2025South San Francisco, CaliforniaCIK: 0001653087Biotechnology
Full company profileView on SEC.gov

Leadership shakeup: 3 executive changes at Alector in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.

The seat is still open. No replacement has been named 368 days after this filing.

See every company with multiple executive changes →

AI Executive Summary

AI-powered analysis of 8-K filing content

Alector committed to cutting its workforce by about 49% (roughly 75 employees) and discontinued the open-label extension and continuation study for latozinemab after Phase 3 INFRONT-3 results, with about $7.7 million in incremental restructuring charges expected. President and Head of R&D Dr. Sara Kenkare-Mitra also resigned, effective December 22, 2025, under a separation agreement.

Key Takeaways

Alector will reduce its workforce by approximately 49%, affecting about 75 employees, to align resources with its strategic priorities, with the reduction expected to be completed in the first half of

The company is discontinuing the open-label extension of the Phase 3 INFRONT-3 trial and the continuation study for latozinemab (AL001) in FTD-GRN, based on the trial results.

3 more takeaways

Related Filings (3)

3 more filings from Alector, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateOct 21, 2025
Item5.02
CategoryExecutive Change
CIK0001653087
Accession #0001193125-25-245102
Risk LevelHIGH
SentimentNegative
Signalrisk
Topics
layoffsrestructuringexecutive departure

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Alector, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.